Aderbasib (INN/USAN, codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation.[1] Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells.[2] Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.
No comments:
Post a Comment